King Pharmaceuticals Canada is one of Canada's newest specialty pharmaceutical companies. Formed in 2006 following the licensing of sales and marketing rights for EpiPen (epinephrine auto-injector) for the emergency treatment of patients suffering from potentially life threatening allergic reactions known as anaphylaxis.

While King Pharmaceuticals Canada is a newly formed company it the first North American  expansion of U.S.A based King Pharmaceuticals (NYSE:KG) which is one of the 50 largest pharmaceutical companies.

King Pharmaceuticals Canada is therapeutically focused in speciality driven markets such as neuroscience, hospital, and acute care medicines.

To learn more about King's Canadian operations please visit www.kingpharm.ca

King Pharmaceuticals Canada is actively seeking pharmaceutical products to compliment current products  in severe allergy,  pain management.

Viable opportunities must either be currently marketed products in the Canadian markets or products which are targeted for approval in less then 24 months.

King Pharmaceuticals Canada is open to a variety of opportunities including co-promotions, in-licensing, and company acquisitions.

To learn more about King's Canadian operations please visit www.kingpharm.ca